FDAnews
www.fdanews.com/articles/108392-rosetta-collaborators-use-micrornas-to-distinguish-brain-tumors

Rosetta, Collaborators Use MicroRNAs to Distinguish Brain Tumors

July 9, 2008

MicroRNAs (ribonucleic acid) can accurately differentiate primary from metastatic tumors in the brain, according to a new study by Rosetta Genomics and its collaborators.

The recently discovered microRNAs are naturally occurring, small RNAs that have been shown to have different expression profiles in various pathological conditions.

The study’s findings demonstrate microRNAs’ potential to act as biomarkers that can be used in diagnostic tests to identify primary tumors in patients with brain cancers, the company said.